Comparative Pharmacology
Head-to-head clinical analysis: TRIAVIL 2 25 versus TRIAVIL 4 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIAVIL 2 25 versus TRIAVIL 4 25.
TRIAVIL 2-25 vs TRIAVIL 4-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRIAVIL 2-25 contains perphenazine and amitriptyline. Perphenazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the brain, reducing dopaminergic neurotransmission. It also has alpha-adrenergic and anticholinergic effects. Amitriptyline is a tricyclic antidepressant that inhibits the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft. It also blocks histamine H1, muscarinic, and alpha-adrenergic receptors.
TRIAVIL (amitriptyline/perphenazine) combines a tricyclic antidepressant (amitriptyline) that inhibits reuptake of norepinephrine and serotonin, and a phenothiazine antipsychotic (perphenazine) that blocks dopamine D2 receptors, serotonin 5-HT2 receptors, and alpha-adrenergic receptors, with additional anticholinergic, antihistaminergic, and antiemetic properties.
One tablet (2 mg perphenazine / 25 mg amitriptyline) orally 3 to 4 times daily; maintenance dose: 2 to 4 tablets daily.
One tablet (perphenazine 4 mg / amitriptyline 25 mg) orally 3 to 4 times daily. Maximum: 8 tablets daily.
None Documented
None Documented
Amitriptyline: 9-25 hours (mean 15 hours); perphenazine: 9-12 hours. Steady-state achieved in 3-7 days.
Amitriptyline: 13–36 hours (mean ~21 hours); perphenazine: 8–21 hours (mean ~12 hours); steady-state achieved in 3–10 days.
Primarily renal (approximately 70-80% as metabolites, <5% unchanged for amitriptyline; perphenazine excreted renally and fecally).
Renal: ~70% as metabolites (including amitriptyline and perphenazine metabolites) and <5% unchanged; fecal: ~30% via bile; enterohepatic recirculation occurs.
Category C
Category C
Antidepressant-Antipsychotic Combination
Antidepressant-Antipsychotic Combination